Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Monalisa Khuntia"'
Publikováno v:
Diabetes. 70
SGLT2 inhibitors have gained appreciation following their acceptance as a treatment modality for people with type 2 diabetes. These agents promote glucosuia blocking the reabsorption of glucose from the proximal convoluted tubules in the kidneys. Due
Autor:
Laxminarayan Mahapatra, Soumya Sucharita, Abhay Kumar Sahoo, Monalisa Khuntia, Hariballav Mahapatra
Publikováno v:
Endocrine Abstracts.
Autor:
Monalisa Khuntia, Laxminarayan Mahapatra, Soumya Sucharita, Hariballav Mahapatra, Abhay Kumar Sahoo
Publikováno v:
Endocrine Abstracts.
Publikováno v:
Endocrine Abstracts.
Autor:
Abhay Kumar Sahoo, Susant Mishra, Apurba Ranjan Jena, Ranjit Kumar Khatua, Monalisa Khuntia, Sreeya Das, Laxminarayan Mahapatra, Biswaranjan Jena, Ramaballav Mahapatra, Rajesh Kumar Padhi, Hariballav Mahapatra, Sanat Kumar Mishra
Publikováno v:
Diabetes. 69
Background and Aim: Coexistence of hypertension (HTN) and type 2 diabetes (T2DM) multiplies the risk of cardiovascular events. Early identification and prompt management of elevated blood pressure in T2DM has shown to improve the quality of life and
Autor:
Susant Mishra, Biswaranjan Jena, Apurba Ranjan Jena, Sanat Kumar Mishra, Rajesh Kumar Padhi, Sanghamitra Jena, Santosh Kumar Pradhan, Monalisa Khuntia, Hariballav Mahapatra, Ranjit Kumar Khatua, Abhay Kumar Sahoo
Publikováno v:
Journal of the Endocrine Society
Background and aims: Achieving glycemic goals is crucial in the overall management of diabetes. Selecting the right medication for the individual patient is of paramount importance in the present day’s patient centric glucose control. Metformin is
Publikováno v:
Endocrine Practice. 27:S56
Autor:
Abhay Kumar Sahoo, Biswaranjan Jena, Apurba Ranjan Jena, Sreeya Das, Rajesh Kumar Padhi, Hariballav Mahapatra, Susant Mishra, Laxminarayan Mahapatra, Ramaballav Mahapatra, Monalisa Khuntia
Publikováno v:
Diabetes. 67
Objective: People with diabetes gradually require increasing dose of medications to achieve good control. We studied the glycemic response of adding Teneligliptin (Teneli) in T2DM subjects with high HbA1c despite being on stable doses of Met and Glim